Two-day-old rats were exposed to a novel odor and injected with an illness-inducing drug, lithium chloride. When tested at 8 days of age, these pups avoided pine shavings scented with the odor, whereas control pups did not. These results imply that rat pups are capable of associative learning at a much earlier age than was thought possible.

Comorbid conditions that pose risks for suicide, especially depression, are prevalent in people living with chronic pain. The true numbers of failed attempts and successful suicides are unknown and may never be determined. Yet risk factors for suicidal ideation are so high in this population that it must be assumed that some proportion of those who die of drug overdoses might have intended to end their lives, not just temporarily relieve their pain. The purpose of this manuscript is to highlight to clinicians the important association between chronic pain and intentional self-harm. Contemporary understanding of the epidemiology of depression and suicide and the relationship to chronic pain will be reviewed. Recommendations for the use of validated and practical screening tools as part of a comprehensive clinical assessment and for approaches to suicide prevention and interventions as crucial components of chronic pain management are outlined.

No abstract

Chronic pain is associated with symptoms that may impair a patient's quality of life, including emotional distress, fatigue, and sleep disturbance. There is a high prevalence of concomitant pain and sleep disturbance. Studies support the hypothesis that sleep and pain have a bidirectional and reciprocal relationship. Clinicians who manage patients with chronic pain often focus on interventions that relieve pain, and assessing and treating sleep disturbance are secondary or not addressed. This article reviews the literature on pain and co-occurring sleep disturbance, describes the assessment of sleep disturbance, and outlines nonpharmacologic and pharmacologic treatment strategies to improve sleep in patients with chronic pain.

The opioid risk tool (ORT) is a commonly employed measure of risk of aberrant drug related behaviors (ADRB) in patients with chronic pain prescribed opioid therapy. In this study the discriminant predictive validity of the ORT was evaluated in a unique cohort of patients with chronic nonmalignant pain (CNMP) on long-term opioid therapy (LTOT) that displayed no evidence of developing an opioid use disorder (OUD) and a sample of patients with CNMP that developed an OUD after commencing opioid therapy. Results revealed that the original ORT was able to discriminate between patients with and without OUDs (OR=1.624; CI 95%: 1.539-1.715, p< 0.001). A weighted ORT eliminating the gender specific history of preadolescent sexual abuse item revealed comparable results (OR= 1.648; CI 95%: 1.539-1.742, p< 0.001). A revised unweighted ORT (ORT-OUD) removing the history of preadolescent sexual abuse item was notably superior in predicting the development of OUD in patients with CNMP on LTOT (OR= 3.085; CI 95%: 2.725-3.493, p< 0.001) with high specificity (0.851; CI 95%: 0.811-0.885), sensitivity (0.854; 95% CI: 0,799-0.898), positive (0.757; CI 95%: 0.709-0.799) and negative (0.914; CI 95%: 0.885-0.937) predictive values. Perspective:The revised ORT (ORT-OUD) is the first tool developed on a unique cohort to predict the risk of developing an OUD in patients with CNMP receiving opioid therapy, as opposed to ADRB that can reflect a number of other issues. The ORT-OUD has clinical utility in providing clinicians a simple, validated method to rapidly screen for the risk of developing OUD in patients on or being considered for opioid therapy.

Accurately assessing the prevalence of misuse, abuse, and addiction in the pain population has been challenging due to inconsistent definitions between studies. Additional high-quality research is needed in this area utilizing consistent definitions and in reducing the risk of opioid-related overdose fatalities.

It has been reported that neonatal rats acquire first-order conditioned aversions to olfactory stimulation experienced prior to drug-induced illness. Experiment 1 demonstrates that the neonate will also acquire a second-order conditioned odor aversion and that the second-order aversion is not affected by extinguishing the first-order aversion. The effectiveness of the secondorder conditioning paradigm (i.e., Si~* US; S 2 -* Sj) and a sequential blocking paradigm (i.e., S t -*US; S 2 ~*Si->US) also were compared. These comparisons revealed (a) that the occurrence of the US in the second phase of the blocking treatment interfered with second-order conditioning (Experiment 3) and (b) that the temporal proximity of US occurrence to the S 2 ~* Si episode was a critical determiner of the degree to which such interference was observed; that is, the more proximate the S 2 -S l and US events, the more US occurrence interfered with second-order conditioning (Experiment 4). Implications of these findings for theories of conditioning are discussed.

While the participating panel members recognize that there currently is a limited evidence base to support the expert panel's recommendations, primary care providers and pain specialists are largely acting today based on anecdote, intuition, and individual experience. The recommendations are meant to begin to provide a framework for standardizing practices for UDM in the treatment of chronic pain, and to serve as a catalyst to advance research that quantifies the effects of UDM on opioid therapy management and patient outcomes.